Detailed Program Schedule

Wednesday, July 20, 2011
16:00-18:00 Registration
18:00-20:00 Welcome Reception

Thursday, July 21, 2011 [.pdf]

Friday, July 22, 2011 [.pdf]

Saturday, July 23, 2011 [.pdf]

Abstracts only[.pdf]

Program Thu., Fri., Sat. [.pdf]

Complete Book 1.2mb [pdf]

Program highlights

SAH triggers recurrent waves of sustained depolarization (cortical spreading depression; CSD) that challenge the cortex at all levels from gene transcription to cerebral blood flow. Recent studies have shown that CSD can induce microvascular constriction resulting in oxygen deprivation and cortical infarction. CSD may therefore complement vasospasm as a mechanism of delayed ischemic lesions and neuro-worsening. Pathologic mechanisms and therapeutic implications of CSD will be explored in experimental and clinical research presented in joint sessions with the Co-Operative Study on Brain Injury Depolarizations (COSBID).

Cerebral vasospasm is the leading potentially treatable cause of death and disability after aneurysmal rupture. Almost 50% of patients who develop vasospasm will progress to cerebral infarction, and 15-20% will develop a disabling stroke or die, despite maximal therapy. With improved management of SAH patients, vasospasm has significantly decreased as a cause of death during the last decades however, rescue therapies for vasospasm are by no means completely effective and additional treatments are needed.

Advancements in neurological monitoring and neurocritical care management likely play a significant role in the reduction in death due to CV after SAH. Following aggressive, early neurosurgical or endovascular intervention to secure the aneurysm, appropriate neurocritical care management is essential to avoiding secondary injury that may adversely impact outcome. We will discuss novel approaches to neurological monitoring and neurocritical care in the management of events after subarachnoid hemorrhage.

We are pleased to welcome Dr. Tomio Sasaki, Professor and Chairman of the Department of Neurosurgery at the Kyushu University Graduate School of Medical Sciences as a keynote speaker for this aspect of the program.

Throughout the program, we will be integrating presentations of basic science and translational research that contribute to clinical trial design and evidence-based management of SAH patients. We are very excited to welcome Dr. Costantino Iadecola, Chief of Division of Neurobiology at Cornell University, New York, as a keynote speaker. Each session will include a review of the current state of research in that area, and selected abstracts chosen for their innovation and potential impact. As well as platform sessions, there will be poster presentations. There will also be awards for best abstracts in three competition categories.